Get informed when a big investor buys or sells
+ FollowOvervalued by 46.6% based on the discounted cash flow analysis.
Loading insider trades…
Loading congress trades…
| Market cap | $1.98 Billion |
|---|---|
| Enterprise Value | - |
| Earnings per Share | $-14.57 |
| Beta | 0.33 |
| Outstanding Shares | 194,261,000 |
| P/E Ratio | -0.9 |
|---|---|
| PEG | 1.18 |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | - |
| Enterprise Value to Net Income | - |
| Total Debt to Enterprise | - |
| Debt to Equity | - |
No data
No data available for the latest quarter.
No data available for the latest quarter.
Nectar Lifesciences Ltd. operates as a pharmaceutical company, involved in the manufacturing and sale of medicinal products across India and globally. Its product portfolio includes a range of active pharmaceutical ingredients (APIs) and...